New Desktop SEM from Thermo Fisher Scientific Helps Manufacturers Improve Quality Control, Production Efficiency and Material Cleanliness

New Desktop SEM from Thermo Fisher Scientific Helps Manufacturers Improve Quality Control, Production Efficiency and Material Cleanliness Easy-to-use Thermo Scientific Phenom ParticleX can characterize particles up to 10 times faster than outsourcing HILLSBORO, Ore., Sept. 18, 2019 /PRNewswire/ — Thermo Fisher Scientific today introduced the Thermo Scientific Phenom ParticleX, a versatile and intuitive desktop scanning electron microscope... Read more

Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

Basel, 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo... Read more

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Basel, 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data... Read more

Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

Basel, 02 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and... Read more

Roche presents positive phase III study results for one-dose Xofluza in children with flu

Basel, 02 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a potentially more convenient treatment option... Read more

Agilent Companion Diagnostic Gains Expanded FDA Approval in Esophageal Squamous Cell Carcinoma (ESCC)

Agilent Companion Diagnostic Gains Expanded FDA Approval in Esophageal Squamous Cell Carcinoma (ESCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify ESCC patients SANTA CLARA, Calif., July 31, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC... Read more

Fujifilm and Axcelead Drug Discovery Partners Begin Collaborating to Advance Drug Discovery Solutions Using iPSCs

Quick Order Contact Account View Cart (0) Log In Why FCDI Partners & Providers FCDI Customer Stories Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services Cardiac Cells iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiomyocytes Diversity Panel MyCell Cardiomyocytes Brugada iCell Cardiomyocytes CPVT (E2311D) MyCell Cardiomyocytes DCM (L35P) MyCell Cardiomyocytes... Read more

Promega 2019 Corporate Responsibility Report Highlights Commitments to Environmental Sustainability, Employee Well-Being and Community Support

Madison, WI USA. (June 26, 2019) Promega Corporation, a global biotechnology manufacturer, today announced publication of its annual Corporate Responsibility Report of sustainable practices and resulting trends through the previous year. The 2019 report documents how, over the last three years, an overall culture of sustainability resulted in an 8% reduction in the company’s carbon-to-revenue footprint. “We not... Read more

New-Generation Incubator Brings the Latest Technology to Mid-Capacity Microplate Cell Culture

New-Generation Incubator Brings the Latest Technology to Mid-Capacity Microplate Cell Culture New Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator delivers robust and reliable culture solution for cell-based pharmaceutical applications BARCELONA, Spain – SLAS EUROPE 2019 – (June 26, 2019) – As the pharmaceutical industry continues to increase its focus on the development of biologics,... Read more